- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00713141
Evaluation of Brain Function Before and After Standard Chemotherapy for Early Breast Cancer
Primary Objective
- To investigate and clearly document the presence and extent of cognitive decline, if any, in women of Asian origin following standard-dose systematic adjuvant chemotherapy for the treatment of breast cancer
- Investigation and establishment of a relationship between degree of oxidative DNA and lipid damage as indicated by plasma and urinary biochemical markers.
Secondary Objective
• To validate the use of hydrogen peroxide and serum amyloid as biomarkers of damage
Studieoversikt
Status
Forhold
Detaljert beskrivelse
As the survival rate and prognosis of cancer improve, there is increasing recognition of the presence of a long term negative impact of standard chemotherapy on cognition, namely in the domains of attention, memory, psychomotor speed and executive functions. The purported incidence varies between 10-50%, the mechanism is unknown and it is unclear who is at risk. This impact has also not been studied and documented in the Asian population.
This proposal outlines a study that intends to prospectively (1) investigate and document the incidence and severity of cognitive impairment following systemic chemotherapy for breast cancer in Asian women in the acute and prolonged setting, and (2) to relate these cognitive changes to damage to DNA and lipids (two major targets of attack by toxic agents) as indicated through tests conducted on blood and urine samples.
Thirty breast cancer patients who will be required to undergo standard chemotherapy will be recruited for a pilot study to determine the acceptability of the procedure and to establish the size of the effects under investigation. A 45-minute neurocognitive assessment will be administered at three time points: before commencement of chemotherapy, and at 6 months and 1 year following completion of chemotherapy. Blood and urine samples will be collected just prior to the commencement of chemotherapy, after the first cycle of chemotherapy, and also at 6 months and 1 year post completion of chemotherapy.
It is hypothesized that (1) there will be decrements in performance on the neurocognitive measures post-chemotherapy; (2) the presence of cognitive decline will correlate with the presence of markers of oxidative damage in the blood and urine samples. The benefits of this project are two fold. Firstly, it will allow research into and documentation of the possible presence of cognitive decline following chemotherapy in Asian women, which is important in allowing patients to make fully-informed consent with regard to treatment. Secondly, if a relationship between the presence of cognitive decline and the presence of biochemical markers of oxidative damage can be established, this can potentially lead to new treatment methods that may reduce the cognitive decline that has been associated with the chemotherapeutic process.
Studietype
Registrering
Kontakter og plasseringer
Studiesteder
-
-
-
Singapore, Singapore
- National University Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Histologically documented breast cancer
- Females greater than 18 years old
- Eastern Cooperative Oncology Group (ECOG) Performance status 0,1,2
- Requires to undergo standard-dose systemic adjuvant chemotherapy
- Patients must be informed of nature of study and sign an informed consent form
Exclusion criteria
a. Dementia/significantly altered mental status that will prohibit the understanding and/or giving of informed consent
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
---|
1
Early breast cancer
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Chiung Ing Wong, MRCP, MB ChB, National University Hospital, Singapore
Studierekorddatoer
Studer hoveddatoer
Studiestart
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- BR03/09/04
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Tidlig brystkreft
-
Western University, CanadaHar ikke rekruttert ennåeTRE (Early Time Restricted Eating) med BCAA | eTRE (Early Time Restricted Eating)Canada
-
Western University, CanadaUkjenteTRE (Early Time Restricted Eating) | lTRE (Late Time Restricted Eating)Canada
-
Hospices Civils de LyonHar ikke rekruttert ennåEarly Childhood Caries (ECC)Frankrike
-
Western University, CanadaHar ikke rekruttert ennåeTRE (Early Time Restricted Eating) | eTRE med BISC (Kort intens trappeklatring)Canada
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital og andre samarbeidspartnereFullførtThe Clinical Application Guide of Conebeam Breast CTKina
-
Novartis PharmaceuticalsFullførtMetastatisk brystkreft (MBC) | Locally Advance Breast Cancer (LABC)Storbritannia, Spania
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UkjentHR-positiv, HER2-negativ og PIK3CA Mutation Advanced Breast CancerKina
-
Emory UniversityNational Cancer Institute (NCI)TilbaketrukketPrognostisk stadium IV brystkreft AJCC v8 | Metastatisk malign neoplasma i hjernen | Metastatisk brystkarsinom | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeAnatomisk stadium IV brystkreft AJCC v8 | Prognostisk stadium IV brystkreft AJCC v8 | Metastatisk malign neoplasma i beinet | Metastatisk malign neoplasma i lymfeknutene | Metastatisk malign neoplasma i leveren | Metastatisk brystkarsinom | Metastatisk malign neoplasma i lungen | Metastatisk malign neoplasma... og andre forholdForente stater, Canada, Saudi-Arabia, Korea, Republikken
-
InvestigatorUrologyIBSALInstituto de Investigación Biomédica de SalamancaUkjentEtabler effektiviteten mellom de fire ordningene når det gjelder aggressiviteten til svulstene i henhold til Gleason-klassifiseringen | Etabler effektiviteten mellom de fire ordningene når det gjelder sykelighet knyttet til teknikken | Etablere effektiviteten mellom de fire ordningene... og andre forholdSpania